Clinical Trial Update: The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating IBI351 with cetuximab beta plus FOLFIRI as first-line and cetuximab beta alone as second-line therapy for metastatic colorecta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• IBI351

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Colorectal Cancer Metastatic, KRAS G12C Mutation | Phase 2 | Status: NOT_YET_RECRUITING